Compare LFST & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFST | TMDX |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | 2021 | 2019 |
| Metric | LFST | TMDX |
|---|---|---|
| Price | $11.22 | $76.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $9.83 | ★ $148.22 |
| AVG Volume (30 Days) | ★ 3.4M | 829.8K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $1,424,285,000.00 | $605,494,000.00 |
| Revenue This Year | $17.18 | $24.25 |
| Revenue Next Year | $14.02 | $18.75 |
| P/E Ratio | ★ N/A | $371.40 |
| Revenue Growth | 13.85 | ★ 37.13 |
| 52 Week Low | $3.74 | $60.11 |
| 52 Week High | $11.76 | $156.00 |
| Indicator | LFST | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 61.23 | 55.39 |
| Support Level | $6.23 | $64.87 |
| Resistance Level | $11.69 | $79.60 |
| Average True Range (ATR) | 0.38 | 3.26 |
| MACD | -0.12 | 0.29 |
| Stochastic Oscillator | 53.46 | 70.63 |
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.